alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
EXHIBIT 34.2




[Letterhead of KPMG]




Report of Independent Registered Public Accounting Firm




The Board of Directors


Citibank, N.A.:





We have examined management’s assertion, included in the accompanying Management’s Assertion of Compliance, that the Agency and Trust division of Citibank, N.A. (or “Company”) complied with the servicing criteria set forth in Item 1122(d) of the Securities and Exchange Commission’s Regulation AB for publicly-issued (i.e., transaction-level reporting initially required under the Securities Exchange Act of 1934, as amended) and certain privately issued (i.e., for which transaction-level reporting is required pursuant to contractual obligation) automobile loan or lease-backed securities, equipment loan-backed securities and student loan-backed securities issued on or after January 1, 2006 for which the Company provides trustee and paying agent services (the “Platform”), except for servicing criteria 1122(d)(1)(i)-1122(d)(1)(iv), 1122(d)(2)(i), 1122(d)(2)(iii), 1122(d)(2)(vi)-1122(d)(2)(vii), 1122(d)(3)(i) and 1122(d)(4)(i)-1122(d)(4)(xv), which the Company has determined are not applicable to the activities it performs with respect to the Platform, as of and for the twelve months ended December 31, 2011.  Management is responsible for the Company’s compliance with the servicing criteria. Our responsibility is to express an opinion on management’s assertion about the Company’s compliance based on our examination.





Our examination was conducted in accordance with the standards of the Public Company Accounting Oversight Board (United States)and, accordingly, included examining, on a test basis, evidence about the Company’s compliance with the servicing criteria specified above and performing such other procedures as we considered necessary in the circumstances.  Our examination included testing selected asset-backed transactions and securities that comprise the Platform, testing selected servicing activities related to the Platform, and determining whether the Company processed those selected transactions and performed those selected activities in compliance with the servicing criteria.  Furthermore, our procedures were limited to the selected transactions and servicing activities performed by the Company during the period covered by this report.  Our procedures were not designed to determine whether errors may have occurred either prior to or subsequent to our tests that may have affected the balances or amounts calculated or reported by the Company during the period covered by this report for the selected transactions or any other transactions. We believe that our examination provides a reasonable basis for our opinion.  Our examination does not provide a legal determination on the Company’s compliance with the servicing criteria.





In our opinion, management’s assertion that the Company complied with the aforementioned servicing criteria as of and for the twelve months ended December 31, 2011 is fairly stated, in all material respects.





/s/ KPMG LLP





Chicago, Illinois


February 28, 2012
**Exhibit 32.2**

** **

**CERTIFICATIONOF DISCLOSURE PURSUANT TO**

**18 U.S.C.SECTION 1350,**

**AS ADOPTEDPURSUANT TO**

**SECTION 906OF THE SARBANES-OXLEY ACT OF 2002**

 

 

In connectionwith the amended Annual Report of TPT Global Tech, Inc. (the “Company”) on Form 10-K for the period ending December31, 2018 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Gary L. Cook,Chief Financial Officer and Principal Accounting Officer of the Company, certify, pursuant to 18 USC section 1350, as adoptedpursuant to section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge and belief:

 

(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operationsof the Company.

 

Dated: April10, 2019

 

/s/Gary L. Cook 

_____________________________________________________

Gary L. Cook,

Chief FinancialOfficer & Principal Accounting Officer

 

This certificationaccompanies the Report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent requiredby the Sarbanes-Oxley Act of 2002, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of1934, as amended.
# Official Journal L 298/2011

| | ISSN 1977-0677
  doi:10.3000/19770677.L_2011.298.eng |
| --- | --- |
| Official Journal
  of the European Union | L 298 |
| | |
| English edition | Legislation | Volume 5416 November 2011 |

ISSN 1977-0677

doi:10.3000/19770677.L_2011.298.eng

Official Journal

of the European Union

L 298

English edition

Legislation

Volume 5416 November 2011

---

| Contents | | II   Non-legislative acts | page |
| --- | --- | --- | --- |
| | | REGULATIONS |
| | * | Commission Regulation (EU) No 1149/2011 of 21 October 2011 amending Regulation (EC) No 2042/2003 on the continuing airworthiness of aircraft and aeronautical products, parts and appliances, and on the approval of organisations and personnel involved in these tasks (1) | 1 |

Contents

II   Non-legislative acts

page

REGULATIONS

*

Commission Regulation (EU) No 1149/2011 of 21 October 2011 amending Regulation (EC) No 2042/2003 on the continuing airworthiness of aircraft and aeronautical products, parts and appliances, and on the approval of organisations and personnel involved in these tasks (1)

1

| | |
| --- | --- |
| | (1)   Text with EEA relevance |

---

(1)   Text with EEA relevance

1

| EN | Acts whose titles are printed in light type are those relating to day-to-day management of agricultural matters, and are generally valid for a limited period.
  The titles of all other Acts are printed in bold type and preceded by an asterisk. |
| --- | --- |

EN

Acts whose titles are printed in light type are those relating to day-to-day management of agricultural matters, and are generally valid for a limited period.

The titles of all other Acts are printed in bold type and preceded by an asterisk.
EX-10.1


  Exhibit 10.1

   

   

   

   

   

  April 6, 2022

  Javier B. Szwarcberg, M.D., M.P.H.

  [***]

   

  Re: Amendment to Offer Letter

  Dear Javier,

  This letter agreement (this “Amendment”) amends the offer letter dated December 29, 2021 (the “Offer Letter”), between you and Spruce Biosciences, Inc. (the “Company”), as set forth below.

  The eighth paragraph of the Offer Letter is hereby amended and restated in its entirety as follows: 

  “You will be entitled to participate in the Company's Severance and Change of Control Plan (the "Severance Plan"), a copy of which will be separately provided to you, provided that with respect to the Second Stock Option only, the vesting acceleration benefits under the Severance Plan applicable to a Change in Control Termination (as defined in the Severance Plan) will only apply for a Change in Control (as defined in the Severance Plan) with an effective date on or after the first anniversary of your Start Date.”

  Other than as provided in this Amendment, the terms and conditions of your employment with the Company as set forth in the Offer Letter remain unchanged. This Amendment, together with the Offer Letter and the other plans, policies and agreements referred to therein, shall constitute the complete agreement between you and Company with respect to the terms and conditions of your employment. Further, the terms set forth herein supersede and replace any and all prior agreements or representations made to you concerning the subject matter hereof, whether written or oral.  This letter agreement cannot be modified, amended or extended except in a writing signed by you and a duly authorized officer of the Company.

   

  2001 Junipero Serra Boulevard | Suite 640 | Daly City, CA 94014

  

   

   

   

  Please acknowledge your acceptance of the modifications to the Offer Letter as set forth in this Amendment by signing and returning the original to the Company.

  Sincerely,

   

  /s/ Michael Grey			

  Michael Grey

  Spruce Biosciences, Inc.

  Accepted by:

  /s/ Javier B. Szwarcberg, M.D., M.P.H.	

  [signature]

  Javier B. Szwarcberg, M.D., M.P.H.    		

  [name]

  April 6, 2022                                        	

  Date

   

   

  2001 Junipero Serra Boulevard | Suite 640 | Daly City, CA 94014
Exhibit
32.1




CERTIFICATION
PURSUANT TO SECTION 906


OF
THE SARBANES-OXLEY ACT OF 2002




In
connection with the Quarterly Report on Form 10-Q of Regency Affiliates, Inc.
(the "Company") for the quarter ended March 31, 2008 filed with the Securities
and Exchange Commission on the date hereof (the "Report"), I, Laurence S. Levy,
President and Chief Executive Officer of the Company, certify, pursuant to 18
U.S.C. Section 1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002, that:




(1)  The
Report fully complies with the requirements of Section 13(a) or 15(d) of the
Securities Exchange Act of 1934; and




(2)  The
information contained in the Report fairly presents, in all material respects,
the consolidated financial condition of the Company as of the dates presented
and the consolidated result of operations of the Company for the periods
presented.




Dated:  September
12, 2008


By:
                /s/ Laurence
      S. LevyLaurence
      S. Levy
                  President
      andChief
      Executive Officer
**Avis juridique important**

*|*

# 11965F017

**TREATY ESTABLISHING A SINGLE COUNCIL AND A SINGLE COMMISSION OF THE EUROPEAN COMMUNITIES, CHAPTER II: THE COMMISSION OF THE EUROPEAN COMMUNITIES, ARTICLE 17***Official Journal L 152 , 13/07/1967 P. 0006*

++++

ARTICLE 17  

THE COMMISSION SHALL ACT BY A MAJORITY OF THE NUMBER OF MEMBERS PROVIDED FOR IN ARTICLE 10 .  

A MEETING OF THE COMMISSION SHALL BE VALID ONLY IF THE NUMBER OF MEMBERS LAID DOWN IN ITS RULES OF PROCEDURE IS PRESENT .
DISTRICT COURT OF APPEAL OF THE STATE OF FLORIDA

FOURTH DISTRICT

ROBB KACHUR SEBASTY,

Appellant,

v.

STATE OF FLORIDA,

Appellee.

No. 4D18-974

[March 7, 2019]

Appeal from the Circuit Court for the Seventeenth Judicial Circuit, 

Broward County; Elizabeth Anne Scherer, Judge; L.T. Case No. 16-

13700CF10A.

Daniel A. Callahan of Daniel A. Callahan, P.A., Fort Lauderdale, for 

appellant.

Ashley B. Moody, Attorney General, Tallahassee, and Jonathan P. 

Picard, Assistant Attorney General, West Palm Beach, for appellee.

PER CURIAM.

Affirmed.

WARNER, GROSS, JJ., and WEISS, DALIAH, Associate Judge, concur.

* * *

Not final until disposition of timely filed motion for rehearing.
<TABLE> <S> <C>

<ARTICLE> UT
<CIK> 0000100122
<NAME> TUCSON ELECTRIC POWER COMPANY
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                          DEC-31-1998
<PERIOD-END>                               JUN-30-1998
<BOOK-VALUE>                                  PER-BOOK
<TOTAL-NET-UTILITY-PLANT>                    1,922,924
<OTHER-PROPERTY-AND-INVEST>                     59,422
<TOTAL-CURRENT-ASSETS>                         263,553
<TOTAL-DEFERRED-CHARGES>                       317,427
<OTHER-ASSETS>                                  74,759
<TOTAL-ASSETS>                               2,638,085
<COMMON>                                       639,303
<CAPITAL-SURPLUS-PAID-IN>                            0
<RETAINED-EARNINGS>                          (415,560)
<TOTAL-COMMON-STOCKHOLDERS-EQ>                 223,743
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<LONG-TERM-DEBT-NET>                         1,211,795
<SHORT-TERM-NOTES>                                   0
<LONG-TERM-NOTES-PAYABLE>                            0
<COMMERCIAL-PAPER-OBLIGATIONS>                       0
<LONG-TERM-DEBT-CURRENT-PORT>                    1,225
<PREFERRED-STOCK-CURRENT>                            0
<CAPITAL-LEASE-OBLIGATIONS>                    884,720
<LEASES-CURRENT>                                13,578
<OTHER-ITEMS-CAPITAL-AND-LIAB>                 303,024
<TOT-CAPITALIZATION-AND-LIAB>                2,638,085
<GROSS-OPERATING-REVENUE>                      340,689
<INCOME-TAX-EXPENSE>                             1,101 
<OTHER-OPERATING-EXPENSES>                     285,757
<TOTAL-OPERATING-EXPENSES>                     286,858
<OPERATING-INCOME-LOSS>                         53,831
<OTHER-INCOME-NET>                              12,182
<INCOME-BEFORE-INTEREST-EXPEN>                  66,013
<TOTAL-INTEREST-EXPENSE>                        59,547
<NET-INCOME>                                     6,466 
<PREFERRED-STOCK-DIVIDENDS>                          0
<EARNINGS-AVAILABLE-FOR-COMM>                    6,466 
<COMMON-STOCK-DIVIDENDS>                             0
<TOTAL-INTEREST-ON-BONDS>                            0
<CASH-FLOW-OPERATIONS>                          50,371
<EPS-PRIMARY>                                        0
<EPS-DILUTED>                                        0
        


</TABLE>
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Presidio Trust

# AGENCY:

The Presidio Trust. 

# ACTION:

Notice of public meeting. 

# SUMMARY:

In accordance with § 103(c)(6) of the Presidio Trust Act, 16 U.S.C. 460bb note, Title I of Pub. L. 104-333, 110 Stat. 4097, as amended, and in accordance with the Presidio Trust's bylaws, notice is hereby given that a public meeting of the Presidio Trust Board of Directors will be held commencing 6:30 p.m. on Thursday, May 10, 2007, at the Golden Gate Club, 135 Fisher Loop, Presidio of San Francisco, California. The Presidio Trust was created by Congress in 1996 to manage approximately eighty percent of the former U.S. Army base known as the Presidio, in San Francisco, California. 

The purposes of this meeting are to hear presentations from the finalists selected to submit proposals for the development of a Presidio Lodge, to adopt a Philanthropic Recognition Policy, to provide an Executive Director's report, and to receive public comment in accordance with the Trust's Public Outreach Policy. 

Individuals requiring special accommodation at this meeting, such as needing a sign language interpreter, should contact Mollie Matull at 415.561.5300 prior to May 2, 2007. 

*Times:*                         The meeting will begin at 6:30 p.m. on Thursday, May 10, 2007.                     

# ADDRESSES:

The meeting will be held at the Golden Gate Club, 135 Fisher Loop, Presidio of San Francisco. 

# FOR FURTHER INFORMATION CONTACT:

Karen Cook, General Counsel, the Presidio Trust, 34 Graham Street, P.O. Box 29052, San Francisco, California 94129-0052, Telephone: 415.561.5300. 

Dated: April 18, 2007. 

Karen A. Cook, 

General Counsel.

[FR Doc. E7-7738 Filed 4-23-07; 8:45 am] 

BILLING CODE 4310-4R-P
EX-10.42






 Exhibit 10.42 

WARRANT TO SUBSCRIBE TO COMMON SHARES 
  

			
	No 1.	  	Right to subscribe for 312,500 shares of common stock of Ocean Biomedical, Inc., a Delaware corporation, par value of $0.000001 per share.

 THIS IS TO CERTIFY that upon surrender of this warrant at or before 5:00 P.M., eastern standard time, on the expiration date
stated below, at the office of Ocean Biomedical, Inc., 55 Claverick Street #325, Providence, RI 02903, SECOND STREET CAPITAL, LLC is entitled (upon the terms and conditions herein set forth) to subscribe at ELEVEN and No/100 DOLLARS ($11.00)
per share to common shares of the par value of $0.000001 per share of Ocean Biomedical, Inc., a Delaware corporation (hereinafter called the “Company”). 

Such subscription must be made by surrendering this warrant with the subscription form on the reverse hereof completed and signed and either
(i) delivering payment in full at the time of subscription by check or bank draft payable in U.S. funds to the order of Ocean Biomedical, Inc., or (ii) electing to receive only the number of shares which represents the value of the
difference between the fair market value of the shares and the exercise price (a “Cashless Exercise”). 
 Certificates for shares
will be delivered as soon as practicable after subscriptions are received. 
 UNLESS SUBSCRIPTION AND PAYMENT/CASHLESS EXERCISE ELECTION BE SO MADE AT OR
BEFORE 5:00 P.M., EASTERN STANDARD TIME, ON THE EXPIRATION DATE STATED BELOW, THIS WARRANT WILL BECOME WHOLLY VOID AND THE SUBSCRIPTION RIGHT EVIDENCED HEREBY WILL TERMINATE. 

THIS WARRANT IS ISSUED IN ACCORDANCE WITH THE LOAN AGREEMENT BETWEEN THE COMPANY AND SECOND STREET CAPITAL, LLC, DATED FEBRUARY 22, 2022 (THE
“LOAN AGREEMENT”). PURSUANT TO THE LOAN AGREEMENT, IN THE EVENT LENDER TIMELY ELECTS TO EXERCISE ITS “PUT OPTION,” AS DESCRIBED IN THE LOAN AGREEMENT, THIS WARRANT AND ANY OTHER WARRANTS HELD BY LENDER SHALL BE
SURRENDERED BY LENDER UPON PAYMENT BY THE COMPANY OF $250,000.00 AND THIS WARRANT AND ANY OTHER WARRANTS HELD BY LENDER WILL BECOME WHOLLY VOID AND THE SUBSCRIPTION RIGHT EVIDENCED HEREBY WILL TERMINATE. 

Title hereto is transferable, with the same effect as in the case of a negotiable instrument, by delivery by any person in possession hereof, howsoever such
possession may have been acquired; and every taker or holder of this warrant, by accepting the same, agrees thereto with every subsequent taker and holder hereof, as well as with the Company. 

Expiration Date: March 8, 2026 
  

			
	OCEAN BIOMEDICAL, INC.
		
	By:	 	 /s/ Chirinjeev Kathuria

		 	Chirinjeev Kathuria, Executive Chairman



  
 1 














 FORM OF SUBSCRIPTION 

[date] 
  

	To:	 Ocean Biomedical, Inc. 



55 Claverick Street #325 

Providence, RI 02903. 
 The undersigned hereby
subscribes, upon the terms mentioned in the within warrant, for the shares covered thereby, and hereby (check one box): 
  

			
	☐	 	Elects a Cashless Exercise; or
	☐	 	Makes payment of such subscription in full.


  

			
	Subscriber:	 	      

	By:	 	
	Its:	 	      




  
 2
**Exhibit 31.1**    
**CERTIFICATION OF CHIEF EXECUTIVE OFFICER**
I, Bruce M. Zorich, Chief Executive Officer of United Components, Inc. certifythat:
1. I have reviewed this report on Form 10-Q of United Components,Inc.; 2. Based on my knowledge, this report does not contain any untruestatement of a material fact or omit to state a material fact necessaryto make the statements made, in light of the circumstances under whichsuch statements were made, not misleading with respect to the periodcovered by this report; 3. Based on my knowledge, the financial statements, and otherfinancial information included in this report, fairly present in allmaterial respects the financial condition, results of operations andcash flows of the registrant as of, and for, the periods presented inthis report; 4. The registrant’s other certifying officer and I are responsible forestablishing and maintaining disclosure controls and procedures (asdefined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for theregistrant and have:
a) Designed such disclosure controls and procedures, or causedsuch disclosure controls and procedures to be designed under oursupervision, to ensure that material information relating to theregistrant, including its consolidated subsidiaries, is made knownto us by others within those entities, particularly during theperiod in which this report is being prepared; b) Evaluated the effectiveness of the registrant’s disclosurecontrols and procedures and presented in this report our conclusionsabout the effectiveness of the disclosure controls and procedures,as of the end of the period covered by this report based on suchevaluation; and c) Disclosed in this report any change in the registrant’sinternal control over financial reporting that occurred during theregistrant’s most recent fiscal quarter (the registrant’s fourthfiscal quarter in the case of annual report) that has materiallyaffected, or is reasonably likely to materially affect, theregistrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer and I have disclosed,based on our most recent evaluation of internal control over financialreporting, to the registrant’s auditors and the audit committee ofregistrant’s board of directors (or persons performing the equivalentfunctions):
a) All significant deficiencies and material weaknesses in thedesign or operation of internal controls over financial reportingwhich are reasonably likely to adversely affect the registrant’sability to record, process, summarize and report financialinformation; and b) Any fraud, whether or not material, that involves managementor other employees who have a significant role in the registrant’sinternal control over financial reporting.
Date: August 13, 2004       By:  /s/ Bruce M. Zorich     Name: Bruce M. Zorich Title: Chief Executive Officer
CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

 

In connection with the Annual Report of CHINARENEWABLE CONSTRUCTION MATERIALS INC. (the "Company") on Form 10-K for fiscal year ended September 30, 2012, as filedwith the Securities and Exchange Commission on the date hereof (the "Report"), the undersigned, Chief Executive Officer& Chief Financial Officer, certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-OxleyAct of 2002, that to his knowledge:

 

   1. The report fully complies with the requirementsof Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

   2. The information contained in the Report fairlypresents, in all material respects, the financial condition and results of operations of the Company.

 

 

 

 Date:  November 8, 2012                                                           By:/s/ Chi Wu

                                                                                  -------------------------------

                                                                                     ChiWu, CEO and CFO